Stoke Therapeutics Inc - Ordinary Shares

The momentum for this stock is not very good. Stoke Therapeutics Inc - Ordinary Shares is not a good growth stock. Stoke Therapeutics Inc - Ordinary Shares is not very popular among insiders. Tradey thinks it is not wise to invest in Stoke Therapeutics Inc - Ordinary Shares.

News

Stoke Therapeutics (NASDAQ:STOK) Receives "Buy" Rating from HC Wainwright

Zolmax HC Wainwright reaffirmed their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK - Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $35.00 price...\n more…

Stoke Therapeutics presents Zorevunersen data at EEC

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease

Business Wire Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine, today announced highlights from...\n more…

Stoke Therapeutics (STOK) Stock Surges on Potential Genetic Treatment Breakthrough

TipRanks Financial Blog Biotechnology company Stoke Therapeutics ($STOK) is grabbing investors' attention with its Zorevunersen (STK-001) treatment for Dravet syndrome, a severe form of ge...\n more…

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

Seeking Alpha - Long Ideas Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome...\n more…

Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $21.40

Ticker Report Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat reports. One...\n more…